Ylenia Cicirò

Ylenia Cicirò

Auto-generated profile, based on publicly available information

Ylenia Cicirò

College of Health, Medicine and Life Sciences, Centre for Genome Engineering and Maintenance, Brunel University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYlenia Cicirò
Ylenia Cicirò
DRDenise Ragusa
Denise Ragusa
ASArturo Sala
Arturo Sala
The identification of clinically-relevant biomarkers is of upmost importance for the management of cancer, from diagnosis to treatment choices. We performed a pan-cancer analysis of the mitotic checkpoint budding uninhibited by benzimidazole 1 gene BUB1, in the attempt to ascertain its diagnostic and prognostic values, specifically in the context of drug response. BUB1 was found to be overexpressed in the majority of cancers, and particularly elevated in clinically aggressive molecular subtypes. Its expression was correlated with clinico-phenotypic features, notably tumour staging, size, invasion, hypoxia, and stemness. In terms of prognostic value, the expression of BUB1 bore differential clinical outcomes depending on the treatment administered in TCGA cancer cohorts, suggesting sensitivity or resistance, depending on the expression levels. We also integrated in vitro drug sensitivity data from public projects based on correlation between drug efficacy and BUB1 expression to produce a list of candidate compounds with differential responses according to BUB1 levels. Gene Ontology enrichment analyses revealed that BUB1 overexpression in cancer is associated with biological processes related to mitosis and chromosome segregation machinery, reflecting the mechanisms of action of drugs with a differential effect based on BUB1 expression.

3 September 2022 in Oncogenesis
Verified
Journal Article
Open access
PDF file
DRDenise Ragusa
Denise Ragusa
YCYlenia Cicirò
Ylenia Cicirò
CFConcetta Federico
Concetta Federico
Salvatore SacconeSalvatore Saccone
Salvatore Saccone
FBFrancesca Bruno
Francesca Bruno
Sabrina TosiSabrina Tosi
Sabrina Tosi
Acute myeloid leukaemia carrying the translocation t(7;12)(q36;p13) is an adverse-risk leukaemia uniquely observed in infants. Despite constituting up to 30% of cases in under 2-year-olds, it remains poorly understood. Known molecular features are ectopic overexpression of the MNX1 gene and generation of a fusion transcript in 50% of patients. Lack of research models has hindered understanding of t(7;12) biology, which has historically focused on MNX1 overexpression rather than the cytogenetic entity itself. Here, we employed CRISPR/Cas9 to generate t(7;12) in the human K562 cell line, and in healthy CD34+ haematopoietic progenitors where the translocation was not sustained in long-term cultures or through serial replating. In contrast, in K562 cells, t(7;12) was propagated in self-renewing clonogenic assays, with sustained myeloid bias in colony formation and baseline depletion of erythroid signatures. Nuclear localisation analysis revealed repositioning of the translocated MNX1 locus to the interior of t(7;12)-harbouring K562 nuclei — a known phenomenon in t(7;12) patients which associates with ectopic overexpression of MNX1. Crucially, the K562-t(7;12) model successfully recapitulated the transcriptional landscape of t(7;12) patient leukaemia. In summary, we engineered a clinically-relevant model of t(7;12) acute myeloid leukaemia with the potential to unravel targetable molecular mechanisms of disease.

11 September 2025 in eLife
Verified
Journal Article
Open access
DRDenise Ragusa
Denise Ragusa
CSChun Wai Suen
Chun Wai Suen
GCGabriel Torregrosa Cortes
Gabriel Torregrosa Cortes
FPFabio Pastorino
Fabio Pastorino
AJAyona Johns
Ayona Johns
CPCristina Pina
Cristina Pina
Current in vitro models of developmental blood formation lack spatio-temporal accuracy and weakly replicate successive waves of hematopoiesis. Herein, we describe a mouse embryonic stem cell (SC)-derived 3D hemogenic gastruloid (haemGx) that captures multi-wave blood formation, progenitor specification from hemogenic endothelium (HE), and generates hematopoietic progenitors capable of short-term engraftment of immunodeficient mice upon maturation in an in vivo niche. We took advantage of the haemGx model to interrogate the origins of infant acute myeloid leukemia (infAML). We focused on MNX1-driven leukemia, representing the commonest genetic abnormality unique to the infant group. Enforced MNX1 expression in haemGx promotes the expansion and in vitro transformation of yolk sac-like erythroid-myeloid progenitors at the HE-to-hematopoietic transition to faithfully recapitulate patient transcriptional signatures. By combining phenotypic, functional, and transcriptional profiling, including at the single-cell level, we establish the haemGx as a useful new model for the study of normal and leukemic embryonic hematopoiesis.

7 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDenise Ragusa
Denise Ragusa
CSChun-Wai Suen
Chun-Wai Suen
GTGabriel Torregrosa-Cortés
Gabriel Torregrosa-Cortés
FPFabio Pastorino
Fabio Pastorino
AJAyona Johns
Ayona Johns
CPCristina Pina
Cristina Pina
Current in vitro models of developmental blood formation lack spatio-temporal accuracy and weakly replicate successive waves of hematopoiesis. Herein, we describe a mouse embryonic stem cell (SC)-derived 3D hemogenic gastruloid (haemGx) that captures multi-wave blood formation, progenitor specification from hemogenic endothelium (HE), and generates hematopoietic progenitors capable of short-term engraftment of immunodeficient mice upon maturation in an in vivo niche. We took advantage of the haemGx model to interrogate the origins of infant acute myeloid leukemia (infAML). We focused on MNX1-driven leukemia, representing the commonest genetic abnormality unique to the infant group. Enforced MNX1 expression in haemGx promotes the expansion and in vitro transformation of yolk sac-like erythroid-myeloid progenitors at the HE-to-hematopoietic transition to faithfully recapitulate patient transcriptional signatures. By combining phenotypic, functional and transcriptional profiling, including at the single-cell level, we establish the haemGx as a useful new model for the study of normal and leukemic embryonic hematopoiesis.

12 August 2025 in eLife preprints
Verified
Preprint
Open access
DRDenise Ragusa
Denise Ragusa
CSChun-Wai Suen
Chun-Wai Suen
GTGabriel Torregrosa-Cortés
Gabriel Torregrosa-Cortés
FPFabio Pastorino
Fabio Pastorino
AJAyona Johns
Ayona Johns
CPCristina Pina
Cristina Pina
Current in vitro models of developmental blood formation lack spatio-temporal accuracy and weakly replicate successive waves of hematopoiesis. Herein, we describe a mouse embryonic stem cell (SC)-derived 3D hemogenic gastruloid (haemGx) that captures multi-wave blood formation, progenitor specification from hemogenic endothelium (HE), and generates hematopoietic progenitors capable of short-term engraftment of immunodeficient mice upon maturation in an in vivo niche. We took advantage of the haemGx model to interrogate the origins of infant acute myeloid leukemia (infAML). We focused on MNX1-driven leukemia, representing the commonest genetic abnormality unique to the infant group. Enforced MNX1 expression in haemGx promotes the expansion and in vitro transformation of yolk sac-like erythroid-myeloid progenitors at the HE-to-hematopoietic transition to faithfully recapitulate patient transcriptional signatures. By combining phenotypic, functional and transcriptional profiling, including at the single-cell level, we establish the haemGx as a useful new model for the study of normal and leukemic embryonic hematopoiesis.

11 September 2025 in bioRxiv
Verified
Preprint
Open access
YCYlenia Cicirò
Ylenia Cicirò
DRDenise Ragusa
Denise Ragusa
EJEmily M. Johnson
Emily M. Johnson
AJAyona Johns
Ayona Johns
SKSina Kanannejad
Sina Kanannejad
CPCristina Pina
Cristina Pina
The t(7;12) translocation is a chromosomal rearrangement characteristic of infant Acute Myeloid Leukemia (AML) that results in ectopic overexpression of the homeobox gene MNX1 . The resulting AML originates in utero and MNX1 transforms fetal, but not adult, hematopoietic progenitors. Using a 3-dimensional (3D) gastruloid model of blood development, we recently showed that t(7;12)-AML originates at the endothelial-to-hematopoietic transition, explaining its characteristic gene expression signature. Herein, we employ that signature to interrogate the transcriptional profiles of hundreds of human cell lines against the GDSC database of drug sensitivities and identify 12 candidate drugs with putative activity against t(7;12)-AML. We employ a cell line in which we engineered the t(7;12) translocation and systematically test the candidate drugs cell surface phenotype and clonogenic assays. Importantly, we identify SNX.2112 as a potential therapeutic agent against t(7;12)-AML. SNX.2112 selectively eliminates leukemia progenitors and colony-initiation in vitro , and selectively decreases MNX1 expression. The same effects are recapitulated in the 3D gastruloid model. Critically, the signature targeted by SNX.2112 uniquely maps to t(7;12) progenitors in single-cell RNA-seq analysis of leukaemia patients. Combinatorial treatment of t(7;12)-engineered cells with cytarabine or mitoxantrone reveals synergy with conventional chemotherapeutic agents, suggesting the potential of SNX.2112 as a targeted and cytotoxicity-sparing therapeutic approach. Overall, we successfully use an integrated computational and multi-model experimental approach to identify a drug vulnerability of t(7;12)-AML which can be explored for clinical potential.